RARE CFO Sells $250k in Stock to Cover Taxes on Vested RSUs
Ultragenyx Pharmaceutical Inc.
Subscribe to track RARE
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
RARE CFO Sells $250k in Stock to Cover Taxes
Company: Ultragenyx Pharmaceutical Inc. (RARE) Form: 4 | Filed: 2025-10-14 Significance: Low
Insider: Horn Howard Title: Chief Financial Officer | Relationship: Officer
Transaction: • Type: Sell (Tax Withholding) • Shares: 7,942 • Price: $31.51 • Value: $250,252 • Owned After: 98,227
Key Insight: This sale was to cover tax obligations from vesting RSUs, a common and non-discretionary transaction with low signaling value, as noted in the filing's footnotes.
Market Context: Sell-to-cover transactions are automated and generally not indicative of an insider's sentiment towards the company's future prospects.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Ultragenyx Pharmaceutical Inc. (RARE)
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Chief Financial Officer executed a non-discretionary "sell-to-cover" transaction to satisfy tax liabilities arising from the vesting of Restricted Stock Units (RSUs).
- Market Impact: Neutral. This type of sale is automated and does not reflect a change in the insider's sentiment or outlook on the company. The market typically does not react to such filings.
Company Information
| Field | Value |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. |
| Ticker Symbol | RARE |
| CIK | 0001515673 |
| Industry | PHARMACEUTICAL PREPARATIONS [2834] |
Insider Information
| Field | Value |
|---|---|
| Name | Horn Howard |
| CIK | 0001786335 |
| Title/Position | Chief Financial Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-10-13 |
| Transaction Code | S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 7,942 |
| Price Per Share | $31.51 |
| Total Value | $250,252.42 |
| Shares Owned After | 98,227 |
| Ownership Type | Direct |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The filing's footnote explicitly states the sale was to cover tax withholdings. This is a common, non-discretionary action that is not based on the insider's view of the company's future performance. It provides no new information to the market.
Volume & Sentiment
- Expected Volume Impact: Negligible. The transaction size is small relative to typical daily trading volume, and the nature of the sale is unlikely to spur additional trading activity.
- Sentiment Indicator: Neutral. This is a routine corporate action, not a bearish signal. The insider still retains a substantial holding.
Investment Insights
Positive Market Indicators
- The insider maintains a significant position of 98,227 shares, valued at over $3 million at the transaction price, indicating continued alignment with shareholder interests.
Risk Factors
- The transaction itself poses no risk. The only risk would be if an investor misinterprets this routine sale as a bearish signal, which it is not.
Key Takeaways
- Non-Discretionary Sale: This was not a voluntary sale based on market conditions but an automated transaction to pay taxes.
- Tax-Motivated: The sole purpose, as stated in the filing, was to cover tax liabilities from vesting RSUs.
- Significant Remaining Stake: The CFO continues to hold a large number of shares, which is a positive sign of long-term confidence.
Contextual Analysis
Timing Significance
The timing of this sale is linked directly to the vesting schedule of the insider's RSU grants, not to any specific market event or internal company development.
Transaction Context
Footnote 1 is crucial: "Represents shares sold to pay required tax withholdings due to the vesting of RSUs." This confirms the transaction is a "sell-to-cover" and should be viewed as having low informational value.
Company Context
This filing should be viewed in the context of Ultragenyx's overall performance, recent clinical trial data, and financial reports. The insider transaction itself is a minor administrative event.
Risk Assessment
Risk Level: Low
Risk Factors
- Misinterpretation Risk: The primary risk is that uninformed market participants might see "Insider Sale" and react negatively without understanding the context.
- No Negative Signal: The transaction is a feature of executive compensation plans and does not signal any underlying issues with the company.
- Routine Filing: This type of Form 4 filing is common for publicly traded companies and their executives.
Market Considerations
- Informed Market: Sophisticated investors and algorithms typically filter out and correctly identify sell-to-cover transactions, mitigating any potential market impact.
- Focus on Fundamentals: Attention should remain on the company's fundamental business drivers rather than on this non-discretionary insider sale.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-14 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.